The FDA announced on Nov. 26, 2025, that Somerset Therapeutics is voluntarily recalling Cisatracurium Besylate Injection USP due to subpotent product risks from out-of-specification assay results. The recall affects 71,310 vials distributed nationwide.
How to tell if you have it
- Brand: Somerset Therapeutics
- Product: Cisatracurium Besylate Injection USP, 20 mg/10 mL*, (2 mg/mL), 10 x 10 mL Multiple-dose Vials per carton
- NDC: 70069-161-01
- Lot Code: A250043
- Expiration Date: 06/30/2026
The hazard
The product is subpotent due to out-of-specification assay results observed during long-term stability testing. The FDA classified this as a Class III recall.
Context
GovInfoNow's records show Somerset Therapeutics has issued four other recalls since June 4, 2020. Recent similar recalls include the Dexamethasone Injection Recall on Feb. 4, 2026, and the Atropine Sulfate Ophthalmic Solution Recall on Dec. 16, 2024. Other recent recalls of similar products include the Clinere Carbamide Peroxide Recall (June 25, 2026) and the Daptomycin Injection Recall (Aug. 6, 2026).